Inotropic Treatment With Levosimendan (SimdaxR)in Heart Surgery

• Status: Terminated
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypothesis: Treatment with levosimendan will preserve myocardial function and hemodynamics after cardiac surgery and lead to reduced stay at intensive care unit

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ullevaal University Hospital
• Treatments: Simendan

Criteria

Inclusion Criteria:

• EF (ejection fraction)<40%

Exclusion Criteria:

• renal failure, liver failure